Financial newsfor AI agents.

Telix Pharmaceuticals (NASDAQ:TLX) aims for $1.5B in revenue next year, driven by its prostate cancer imaging and therapy programs. Key studies include BiPASS for PSMA-PET imaging and OPTIMAL-PSMA for TLX597-Tx therapy. The company also advances programs for brain and kidney cancer, with FDA approvals expected for PIXCLARA and a decision pending for Zircaix. Telix expects six approved products by next year, subject to regulatory approvals.

Revvity reported Q3 earnings, highlighting AI-driven demand growth in high-content screening instruments, with revenue up 4% and backlog expansion across categories. Diagnostics revenue reached $330M, with mid-single-digit growth. The company raised its 2026 organic growth outlook to 5% and expects Q4 revenue of ~$755M. Margins improved, and free cash flow was strong. Revvity plans to discuss its AI strategy and outlook at an Investor Day event.

Phoenix Education Partners (PXED) reported Q4 earnings, highlighting 13% growth in employer-affiliated enrollment, accounting for 36% of total enrollment. The company plans to invest in employer relationships, academic programs, and AI-driven tools. For fiscal 2027, PXED expects $970M-$1B in revenue and $225M-$240M in adjusted EBITDA. The company also announced a 10% dividend increase and a new interim CFO.

Regal Rexnord (RRX) reported Q3 earnings, noting supply chain and manufacturing challenges in its IPS and AMC segments. IPS saw a 9.6% rise in daily orders but a 1.8% decline in organic sales. AMC organic sales increased 25.2%, driven by data center and discrete automation demand. The company raised its 2026 sales outlook to $6.22B and adjusted EPS guidance to $10.60-$10.90. It is reviewing its portfolio, including a potential sale of its AMS business.

Ferrari reported Q3 progress in model changeovers, with deliveries of 849 Testarossa and 296 Speciale Aperta increasing. The company expects Q4 shipments to rise year over year. EBIT margins improved, and net cash stood at €219 million. Ferrari raised full-year guidance, citing personalization strength and lower F1 costs. The Luce model's initial deliveries are expected in Q4, with a strong order book extending into 2028.

Huntsman (HUN) reported Q3 earnings, noting seasonal slowing and higher raw-material costs in North American MDI markets. The company expects 2027 industry MDI growth to be flat to 2% and sees growth opportunities in advanced materials and automotive applications. Huntsman generated $82M in free cash flow in Q3 and anticipates substantial cash inflow in Q4. Europe remains challenging due to high energy costs, while China's market shows stability.